As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
A scientific team from the Chalmers University of Technology and the University of Gothenburg, Sweden, report the discovery of a number of previously unknown antibiotic-resistant genes. The researchers found the genes by searching large volumes of bacterial DNA collected from humans and various environments from all over the world. Their study (“Identification of 76 Novel B1 Metallo-β-Lactamases through Large-Scale Screening of Genomic and Metagenomic Data”) is published in Microbiome.
“Based on a new computational method using an optimized hidden Markov model, we analyzed over 10,000 bacterial genomes and plasmids together with more than 5 terabases of metagenomic data to identify novel metallo-β-lactamase genes. In total, 76 novel genes were predicted, forming 59 previously undescribed metallo-β-lactamase gene families,” write the investigators.
“The ability to hydrolyze imipenem in an Escherichia coli host was experimentally confirmed for 18 of the 21 tested genes. Two of the novel B1 metallo-β-lactamase genes contained atypical zinc-binding motifs in their active sites that were previously undescribed for metallo-β-lactamases. Phylogenetic analysis showed that B1 metallo-β-lactamases could be divided into five major groups based on their evolutionary origin. Our results also show that, except for one, all of the previously characterized mobile B1 β-lactamases are likely to have originated from chromosomal genes present in Shewanella spp. and other Proteobacterial species.”
Several of the 76 newly found genes can provide bacteria with the ability to degrade carbapenems, a widely used class of antibiotics for treating multiresistant bacteria.
“Our study shows that there are lots of unknown resistance genes. Knowledge about these genes makes it possible to more effectively find and hopefully tackle new forms of multiresistant bacteria,” says Erik Kristiansson, Ph.D., professor in biostatistics at Chalmers University of Technology and principal investigator of the study.
“The more we know about how bacteria can defend themselves against antibiotics, the better are our odds for developing effective, new drugs,” adds co-author Joakim Larsson, Ph.D., professor in environmental pharmacology and director of the Centre for Antibiotic Resistance Research at the University of Gothenburg.
“Resistance genes are often very rare, and a lot of DNA data needs to be examined before a new gene can be found,” Dr. Kristiansson says.
Identifying a resistance gene is also challenging if it has not previously been encountered. The research group solved this by developing new computational methods to find patterns in DNA that are associated with antibiotic resistance. By testing the genes they identified in the laboratory, they could then prove that their predictions were correct.
“Our methods are very efficient and can search for the specific patterns of novel resistance genes in large volumes of DNA sequence data,” notes Fanny Berglund, a Ph.D. student in the research group.
The next step for the research groups is to search for genes that provide resistance to other forms of antibiotics.
“The novel genes we discovered are only the tip of the iceberg. There are still many unidentified antibiotic resistance genes that could become major global health problems in the future,” added Dr. Kristiansson.